The HairMax Laser Comb

Hairloss Study Abstract: Inocoterone and acne. The effect of a topical antiandrogen: results of a multicenter clinical trial

Title
Inocoterone and acne. The effect of a topical antiandrogen: results of a multicenter clinical trial [see comments]
Author
Lookingbill DP; Abrams BB; Ellis CN; Jegasothy BV; Lucky AW; Ortiz-Ferrer LC; Savin RC; Shupack JL; Stiller MJ; Zone JJ; et al
Address
Division of Dermatology, Pennsylvania State University College of Medicine, Hershey.
Source
Arch Dermatol, 128: 9, 1992 Sep, 1197-200
Abstract
BACKGROUND AND METHODS--Because acne is androgen dependent, antiandrogen therapy might improve the condition. Inocoterone acetate (RU 882) is a nonsteroidal antiandrogen that binds to the androgen receptor and has antiandrogenic activity in animal models. To test its topical effect on acne, 126 male subjects with facial acne completed a 16-week, multi-center, double-blind study in which the twice-daily application of a 10% solution of inocoterone was compared with vehicle solution. Baseline and monthly examinations included acne lesion counts and general and endocrine laboratory tests. RESULTS--Inflammatory papules and pustules showed greater reduction in the inocoterone-treated subjects than in the subjects treated with vehicle. This difference achieved statistical significance by week 12 (24% reduction vs 10%) and week 16 (26% reduction vs 13%) and, with longitudinal analysis, throughout the course of the study. Global assessments and changes in comedo counts and sebum excretion rates were not significantly different between the groups. No serious adverse reactions were encountered. CONCLUSIONS--In this double-blind study of 126 male subjects with acne, a topical solution of the antiandrogen inocoterone, compared with vehicle, produced a modest but statistically significant reduction in the number of inflammatory acne lesions.
Language of Publication
English
Unique Identifier
92391885
advertisement
Low Level Laser Therapy for Hair Loss
© 2009 SJ Web Holdings Inc. All Rights Reserved.